Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Anavex Life Sciences (AVXL) Reports Data from Review by Independent DSMB for U.S. Phase 2 Clinical Trial of ANAVEX2-73July 31, 2019 7:26 AM Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett SyndromeJuly 29, 2019 7:00 AM